Abbisko Cayman Limited

Equities

2256

KYG0028A1085

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 04:08:35 2024-04-19 am EDT			5-day change	1st Jan Change
2.9 ^HKD	+1.40%		-1.02%	-20.55%

Apr. 10	Abbisko Cayman's Unit Presents Pre-Clinical Study of Liver Cancer Drug at AACR Annual Meeting	MT
Apr. 09	Abbisko Cayman Completes Patient Enrollment for Phase 3 Trial of Joint Tumor Treatment	MT

641,428,350 Ordinary Shares of Abbisko Cayman Limited are subject to a Lock-Up Agreement Ending on 12-APR-2022.

April 11, 2022

641,428,350 Ordinary Shares of Abbisko Cayman Limited are subject to a Lock-Up Agreement Ending on 12-APR-2022. These Ordinary Shares will be under lockup for 182 days starting from 12-OCT-2021 to 12-APR-2022.

Details:
The existing shareholders have agreed not to dispose off any shares for 6 months after the listing date.

Latest news about Abbisko Cayman Limited

Abbisko Cayman's Unit Presents Pre-Clinical Study of Liver Cancer Drug at AACR Annual Meeting	Apr. 09	MT
Abbisko Cayman Completes Patient Enrollment for Phase 3 Trial of Joint Tumor Treatment	Apr. 08	MT
Abbisko Therapeutics Co., Ltd. Completes All Patient Enrollment for the Global Phase III TGCT Trial of Its CSF-1R Inhibitor - Pimicotinib	Apr. 08	CI
Abbisko Cayman's Attributable Loss Narrows as Revenue, Other Gains Rise	Mar. 14	MT
Abbisko Cayman to Buy Back, Cancel Up to HK$100 Million Shares	Mar. 13	MT
Abbisko Cayman Limited commences an Equity Buyback for 70,219,935 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2023.	Mar. 12	CI
Abbisko Cayman Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
Abbisko Cayman Completes Dosing for Phase 1 Trials for Lung Cancer Treatment	Feb. 22	MT
Abbisko Cayman Receives $70 Million Upfront Payment for Licensing of Tumor Treatment	Feb. 05	MT
Abbisko Cayman Trustee Buys 6.1 Million Shares Under Restricted Share Scheme	Feb. 02	MT
European Medicines Agency Grants Orphan Drug Designation to Abbisko's Tumor Drug	Jan. 09	MT
Abbisko Cayman Doses First Participant in Phase 1 Trial for Anti-Tumor Treatment; Shares Fall 3%	Jan. 03	MT
Abbisko Therapeutics Co., Ltd. Completes the First Patient Dose in the Clinical Trial for Its Next-Generation CD73 Inhibitor ABSK051	Jan. 02	CI
Abbisko Cayman Unit Gets US FDA Fast-Track Status for Tenosynovial Giant Cell Tumor Treatment	Dec. 13	MT
Abbisko Therapeutics Announces U.S. FDA Grants Fast Track Designation for CSF-1R Inhibitor Pimicotinib	Dec. 13	CI
Abbisko Cayman Doses First Patient in Phase 2 Trial for Pancreatic Cancer Treatment	Nov. 27	MT
Abbisko Therapeutics Completed the First Patient Dose in the Phase II Advanced Pancreatic Cancer Trial of CSF-1R Inhibitor Pimicotinib in China	Nov. 27	CI
China Approves Abbisko Cayman Subsidiary's Clinical Trial for Tumor Drug	Nov. 09	MT
Abbisko Therapeutics Co., Ltd. Obtains the Clinical Trial Approval from NMPA for its Next-Generation Small Molecule CD73 Inhibitor ABSK051	Nov. 08	CI
US FDA Green Lights Abbisko Subsidiary's Phase 1 Study for Anti-Tumor Drug	Nov. 07	MT
Abbisko Therapeutics Co., Ltd. Presents Two Clinical Updates of Pimicotinib at the 2023 Connective Tissue Oncology Society Annual Meeting	Nov. 06	CI
Abbisko Cayman Presents Clinical Trial Results of Tenosynovial Giant Cell Tumor Drug at Ireland Meeting	Nov. 02	MT
Abbisko Cayman Unit to Present Data on Tenosynovial Giant Cell Tumor Drug at Conference; Shares Rise 10%	23-10-29	MT
China Grants Clinical Study Approval for Abbisko Cayman Unit's Anti-Tumor Drug	23-10-27	MT
Abbisko Cayman Limited to Debut Two Major Clinical Research Results At the 2023 European Society for Medical Oncology	23-10-16	CI

Chart Abbisko Cayman Limited

Duration

Period

More charts

Company Profile

Abbisko Cayman Ltd is a China-based clinical-stage biopharmaceutical company. The Company is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The Company owns two Core Product Candidates, ABSK011 and ABSK091, and 12 other pipeline product candidates. ABSK011 is a potent and highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). ABSK091 is a molecularly targeted product candidate and a highly potent and selective inhibitor of FGFR subtypes 1, 2 and 3. The Company's products are primarily being developed for hepatocellular carcinoma (HCC), urothelial cancer (UC) and gastric cancer (GC).

Sector

Biotechnology & Medical Research

Calendar

2024-08-18 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.644 CNY

Average target price

7.572 CNY

Spread / Average Target

+186.41%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ABBISKO CAYMAN LIMITED	-20.55%	214M
VERTEX PHARMACEUTICALS INCORPORATED	-2.68%	102B
REGENERON PHARMACEUTICALS, INC.	+1.86%	96.07B
ARGENX SE	-1.86%	21.66B
BIONTECH SE	-17.91%	20.77B
GENMAB A/S	-6.91%	18.53B
WUXI APPTEC CO., LTD.	-40.31%	16.91B
BEIGENE, LTD.	-27.60%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.09%	13.33B
SAREPTA THERAPEUTICS, INC.	+20.06%	10.94B

Bio Therapeutic Drugs